



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

25 June 2026
EMADOC-1700519818-3194723
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Rinvoq upadacitinib

On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Rinvoq. The marketing authorisation holder for this medicinal product is Abbvie Deutschland GmbH & Co. KG.

The CHMP adopted a new indication as follows:

Vitiligo

RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.

The previously authorised indications for Rinvoq remain unchanged and are described in the [Summary of product characteristics \(SmPC\)](#).

For information, on 25 June 2026, the CHMP also adopted a new indication for the treatment of severe alopecia areata in adults and adolescents aged 12 years and older. Further details are provided in a dedicated summary of opinion available on the EMA website.

Detailed recommendations for the use of this product will be described in the updated SmPC, which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summary of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

